Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A phase I/II study of twice-weekly ixazomib plus pomalidomide and dexamethasone in relapsed and refractory multiple myeloma.

Haematologica·2026

Same author

Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.

Nature chemical biology·2026

Same author

New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.

Blood cancer discovery·2026

Same author

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.

Nature medicine·2026

Same author

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights.

American journal of hematology·2026

Same author

Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Multiple Myeloma and the Immune Microenvironment.

Yawara Kawano¹, Aldo M Roccaro¹, Irene M Ghobrial¹

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. United States.

Current Cancer Drug Targets

|February 17, 2017

Summary

Recent advances in cancer therapy include immune checkpoint inhibitors for solid tumors. This review explores immune interactions in multiple myeloma (MM), an incurable plasma cell cancer, focusing on the bone marrow microenvironment.

Keywords:

DCs MDSCs Multiple myeloma NK cells effector T cells macrophages checkpoint inhibitors.tregs

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Related Experiment Videos

Last Updated: Mar 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Area of Science:

Oncology
Immunology
Hematology

Background:

Immune therapies, particularly immune checkpoint inhibitors, show promise in solid tumors.
Multiple myeloma (MM) is a plasma cell neoplasm often associated with immune deficiencies.
The bone marrow microenvironment plays a crucial role in MM progression and immune evasion.

Purpose of the Study:

To review current knowledge on the interaction between malignant plasma cells and the bone marrow immune microenvironment.
To highlight the challenges in developing immune therapies for MM due to its complex microenvironment and tumor heterogeneity.

Main Methods:

Literature review of pre-clinical models and clinical trials.
Analysis of the interplay between malignant plasma cells and immune cells within the bone marrow.

Main Results:

MM progression is linked to an immunosuppressive bone marrow milieu that promotes immune escape.
Despite treatment advances, MM remains largely incurable, necessitating novel therapeutic strategies.

Conclusions:

Targeting both the MM clone and its immune microenvironment is vital for effective treatment.
Understanding the complex bone marrow microenvironment is key to developing successful immune therapies for MM.